To the Editor The recent meta-analysis published by Jacobsen and colleagues1 in JAMA Dermatology amalgamated all available evidence pertaining the role of vismodegib for locally advanced and metastatic basal cell carcinoma. Well-conducted meta-analyses can provide more accurate estimates of response and safety and investigate further the reasons for clinical discrepancies across studies.2
Lima JPDSN. Statistical Concerns on Vismodegib for Basal Cell Carcinoma Meta-analysis. JAMA Dermatol. 2017;153(4):337. doi:10.1001/jamadermatol.2016.5689
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: